M D Hughes

Power considerations for clinical trials using multivariate time-to-event data.

M D Hughes, M. Hughes, 1997, Statistics in medicine.

A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team.

M A Fischl, M D Hughes, S. Hammer, 1997, The New England journal of medicine.

Analysis and design issues for studies using censored biomarker measurements with an example of viral load measurements in HIV clinical trials.

M D Hughes, M. Hughes, 2000, Statistics in medicine.

Within-subject variation in CD4 lymphocyte count in asymptomatic human immunodeficiency virus infection: implications for patient monitoring.

D S Stein, M D Hughes, M. Hughes, 1994, The Journal of infectious diseases.

Evaluating surrogate markers.

M D Hughes, V DeGruttola, S L Welles, 1995, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

Dose‐Finding Designs for HIV Studies

J O'Quigley, M D Hughes, M. Hughes, 2001, Biometrics.

Stopping guidelines for clinical trials with multiple treatments.

M D Hughes, M. Hughes, 1993, Statistics in medicine.

Reporting Bayesian analyses of clinical trials.

M D Hughes, M. Hughes, M. Hughes, 1993, Statistics in medicine.

CD4 cell count as a surrogate endpoint in HIV clinical trials: a meta‐analysis of studies of the AIDS Clinical Trials Group

M J Daniels, M A Fischl, M D Hughes, 1998, AIDS.